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Abstract
Background: Plasma tenofovir (TFV) trough concentrations may be relevant for tenofovir disoproxil fumarate
(TDF)-induced renal dysfunction. The purpose of this study was to determine the association between plasma TFV
trough concentrations and TDF-induced renal dysfunction in Japanese patients with human immunodeficiency
virus (HIV) infection.
Methods: A 48-week, retrospective cohort study was performed with Japanese patients with HIV infection who
started a TDF-containing combination antiretroviral therapy regimen. Plasma TFV trough concentrations were
obtained at steady state. The following variables were included in the analysis: sex, age, body weight, body mass
index (BMI), serum creatinine, CD4+ cell count, HIV-RNA, concomitant medications, comorbidities, plasma TFV
trough concentrations, and estimated glomerular filtration rate (eGFR). For comparisons of variables, we used
Mann-Whitney U tests or Fisher’s exact tests. Then, variables associated with renal dysfunction in the univariate
analysis were entered into correlation analysis.
Results: The analysis included 11 patients. The rate of decrease in eGFR was significantly correlated with body
weight (Spearman correlation = −0.645, p = 0.041), BMI (Spearman correlation = −0.682, p = 0.031), and plasma TFV
trough concentrations (Spearman correlation = 0.709, p = 0.025).
Conclusions: Despite the small sample size, our findings suggest that higher plasma TFV trough concentrations
may cause TDF-induced renal dysfunction. To prevent TDF-induced renal dysfunction, we propose that individual
monitoring of plasma TFV trough concentrations should be performed in Japanese patients with HIV infection.
Keywords: Combination antiretroviral therapy, HIV, Plasma tenofovir trough concentration, Renal dysfunction,
Tenofovir disoproxil fumarate, Therapeutic drug monitoring
Background
Tenofovir disoproxil fumarate (TDF) belongs to the nu-
cleotide reverse transcriptase inhibitor (NRTI) class of
antiretroviral drugs (ARVs) and is a preferred compo-
nent of first-line regimens in the US Department of
Health and Human Services guidelines [1]. Therefore,
promoting safe use of TDF is important during the
management of long-term combination antiretroviral
therapy (cART). Although TDF has a good safety profile,
TDF-induced renal dysfunction is a well-known adverse
effect [2, 3].
The most notable adverse effect with TDF is renal dys-
function, and one study reported that the incidence of
TDF-induced renal dysfunction was high in Japanese pa-
tients [4]. TDF is rapidly converted to tenofovir (TFV)
following absorption, and plasma TFV trough concentra-
tions may be relevant for TDF-induced renal dysfunc-
tion. High plasma TFV trough concentrations are
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reportedly associated with a decrease in glomerular
function [5]. Furthermore, several studies conducted in
Japan reported that low body weight and genetic poly-
morphisms of drug transporter genes are significantly
associated with TDF-induced renal dysfunction [4, 6].
However, reports of the association between plasma
TFV trough concentrations and TDF-induced renal dys-
function in Japanese patients with human immunodefi-
ciency virus (HIV) infection are lacking. Moreover, the
effect of plasma TFV trough concentrations on renal
dysfunction is not guaranteed to be the same between
Japanese patients and patients of other ethnic groups.
For safe use of TDF in Japan, the risk factors for TDF-
induced renal dysfunction in Japanese patients need to
be understood.
Therapeutic drug monitoring (TDM) is an important
clinical technique for personalized medicine. In ART,
TDM is recommended in specific clinical scenarios, such
as for cases in which pathophysiological changes (e.g.,
renal dysfunction) and/or drug-drug interactions ad-
versely affect pharmacokinetics [1, 7]. However, TDM
for cART is not recommended for routine use in the
clinical care of HIV-infected patients because of a lack
of large prospective studies showing that TDM improves
clinical or virologic outcomes [1]. We anticipated that
clarifying the usefulness of monitoring plasma TFV
trough concentrations could prevent TDF-induced renal
dysfunction.
Therefore, the purpose of this study was to determine
the association between plasma TFV trough concentra-
tions and TDF-induced renal dysfunction.
Methods
Patients
A 48-week, retrospective cohort study was performed in
Sapporo Medical University Hospital. Data for HIV-
infected patients who started a TDF-containing cART
regimen between August 2008 and October 2013 were
collected from the medical records. Patients who re-
ceived cART with TDF for at least 2 weeks were enrolled
in this exploratory study. Patients with renal disease that
could affect renal function were excluded from the ana-
lysis. All the patients provided written informed consent
before enrollment, and the protocol was approved (25–
152) by the ethical review board of Sapporo Medical
University.
Measurements
Patients with plasma TFV trough concentration mea-
surements performed at steady state ≥21 h after drug in-
take were included in the analysis. Information about
the time of last drug intake was reported at the time of
sample collection. Pre-dose blood samples were col-
lected in heparinized tubes and centrifuged for 10 min
at 3000 rpm; the resultant plasma was removed and
stored at −20 °C until analysis. Plasma TFV concentra-
tions were analyzed using high-performance liquid chro-
matography, and fluorescence was detected at 254 nm
for excitation and 425 nm for emission (BML Inc.,
Japan). Estimated glomerular filtration rate (eGFR) was
calculated using the Japanese equation that was devel-
oped by the Japanese Society of Nephrology, eGFR =
194 × [serum creatinine]-1.094 × [age]-0.287 × [0.739 for
women] [8]. Renal function was classified as follows:
stage 1, eGFR ≥90 mL/min · 1.73 m2; stage 2, 90 >
eGFR ≥ 60 mL/min · 1.73 m2; stage 3, 60 > eGFR ≥
30 mL/min · 1.73 m2; stage 4, 30 > eGFR ≥ 15 mL/min ·
1.73 m2; and stage 5, eGFR <15 mL/min · 1.73 m2 [9].
Renal dysfunction was defined based on the progression
of classified chronic kidney disease (CKD) stages after
treatment [10]. The rate of decrease in eGFR was
Table 1 Patient characteristics at baseline
Study patients
N = 11
Male sex, n (%) 11 (100)
Age (years) a 35 (32–45)
Body weight (kg) a 56.1 (51.6–67.3)
BMI (kg/m2) a 18.2 (17.6–22.8)
BSA (m2) 1.69 (1.60–1.79)
Serum creatinine (mg/dL) a 0.80 (0.70–0.80)
eGFR (mL/min · 1.73 m2) a 96.1 (81.9–103.1)






CD4+ cell count (/μL) a 119 (37–211)
HIV RNA viral load (log10/mL)
a 4.83 (4.61–5.85)
Protease inhibitors (ritonavir-boosted), n (%) 7 (63.6)
Protease inhibitors (unboosted), n (%) 0 (0)
NNRTIs, n (%) 0 (0)
INSTIs, n (%) 4 (36.4)
Concurrent use of a nephrotoxic drug, n (%) 4 (36.4)
Hypertension, n (%) 0 (0)
Diabetes, n (%) 0 (0)
Hepatitis B, n (%) 3 (27.3)
Hepatitis C, n (%) 0 (0)
Plasma TFV concentration (ng/mL) a 64.0 (56.0–90.5)
BMI body mass index, BSA body surface area, eGFR estimated glomerular
filtration rate, CKD chronic kidney disease, NNRTIs non-nucleoside reverse-
transcriptase inhibitors, INSTIs integrase strand transfer inhibitors, TFV tenofovir
aValues are reported as median (interquartile range)
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defined as the maximum rate of decrease in eGFR from
baseline during the study period.
Other variables included in the analysis were sex, age,
body weight, body mass index (BMI), body surface area
(BSA), serum creatinine concentration, CD4+ cell count,
HIV-RNA, concomitant medications, comorbidities, and
plasma TFV trough concentrations.
Statistical analysis
The time from baseline to renal dysfunction was ana-
lyzed using the Kaplan-Meier method. Baseline charac-
teristics were compared between patients with and
without renal dysfunction using Mann-Whitney U tests
or Fisher’s exact tests. Univariate analysis was conducted
to reduce the list of potential variables associated with
renal dysfunction. The potential variables associated
with renal dysfunction with p ≤ 0.1 in the univariate ana-
lysis were entered into correlation analyses. Statistical
significance was defined as a two-sided p < 0.05. All ana-
lyses were performed using StatMate IV (ATMS Co.
Ltd., Tokyo, Japan).
Results
Of the 12 patients who were enrolled, one patient was
excluded due to a congenital solitary kidney. Patient
characteristics are presented in Table 1. All of the study
patients were men and had a relatively low body weight
(median body weight, 56.1 kg). No patient had comor-
bidities such as hypertension, diabetes, or hepatitis C.
The cART regimens included a protease inhibitor for
63.6 % of the patients (n = 5, darunavir/ritonavir; n = 2,
fosamprenavir/ritonavir) and an integrase strand transfer
inhibitor (raltegravir) for 36.4 % of the patients. The me-
dian time to plasma TFV trough concentration measure-
ments was 9 weeks after starting a TDF-containing
cART regimen.
For the seven patients (63.6 %) in whom renal dys-
function occurred, it occurred within 24 weeks from
cART initiation. The cumulative incidence of renal dys-
function in these patients was 9.1, 27.3, 45.5, 54.5, and
63.6 % at 4, 8, 12, 16–20, and 24–48 weeks, respectively.
The changes in classified CKD stage after treatment in
these patients were from stage 1 to 2, stage 1 to 3, and
stage 2 to 3 in 3, 2, and two patients, respectively.
Table 2 compares the baseline characteristics between
patients with and without renal dysfunction. The rate of
decrease in eGFR was significantly different between the 2
groups (p = 0.008). In patients with renal dysfunction, age
and plasma TFV trough concentrations tended to be
higher, and weight and BMI tended to be lower. Data re-
garding the 11 patients are given in Additional file 1.
The rate of decrease in eGFR was not significantly cor-
related with age (Fig. 1a, Spearman correlation = 0.403,
p = 0.203), but was significantly correlated with weight
(Fig. 1b, Spearman correlation = −0.645, p = 0.041), BMI
(Fig. 1c, Spearman correlation = −0.682, p = 0.031), and
plasma TFV trough concentrations (Fig. 1d, Spearman
correlation = 0.709, p = 0.025).
Discussion
We showed that higher plasma TFV trough concentra-
tions tended to be associated with a decrease in eGFR
after starting cART. In principle, ARVs are required for
a person’s entire lifetime. Most of the NRTI class of






Age (years) a 45.0 (38.0–52.0) 29.5 (24.0–35.8) 0.072
Body weight (kg) a 52.2 (49.4–62.9) 60.8 (59.0–68.8) 0.078
BMI (kg/m2) a 17.7 (17.2–20.9) 21.3 (20.2–23.8) 0.078
BSA (m2) a 1.60 (1.57–1.77) 1.70 (1.69–1.79) 0.169
Serum creatinine (mg/dL) a 0.70 (0.65–0.80) 0.80 (0.78–0.83) 0.163
eGFR (mL/min · 1.73 m2) a 96.1 (85.9–102.9) 90.4 (82.7–104.2) 0.925
Rate of decrease in eGFR (%) a 33.2 (24.3–38.2) 11.7 (8.0–12.9) 0.008
CD4+ cell count (/μL) a 58 (36–133) 204 (99–320) 0.149
HIV RNA viral load (log10/mL)
a 4.63 (4.52–5.84) 5.33 (4.82–5.92) 0.395
Protease inhibitors (ritonavir-boosted), n (%) 4 (57.1) 3 (75.0) 1.000
INSTIs, n (%) 3 (42.9) 1 (25.0) 1.000
Concurrent use of a nephrotoxic drug, n (%) 2 (28.6) 2 (50) 0.576
Hepatitis B, n (%) 3 (42.6) 0 (0) 0.236
Plasma TFV concentration (ng/mL) a 88.0 (67.0–102.5) 56.0 (50.5–60.5) 0.073
BMI body mass index, BSA body surface area, eGFR estimated glomerular filtration rate, INSTIs integrase strand transfer inhibitors, TFV tenofovir
aValues are reported as median (interquartile range)
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ARVs that are used as first-line regimens are of the renal
excretion type. Therefore, choosing ARVs for patients
with renal dysfunction is often difficult. Based on our re-
sults, we propose individual monitoring of plasma TFV
trough concentrations in Japanese patients to prevent
TDF-induced renal dysfunction.
Our data indicated that special attention should be
given to TDF-induced renal dysfunction within 24 weeks
from cART initiation. Not only did renal dysfunction de-
velop within 24 weeks for all 7 patients in the present
study, eGFR rapidly decreased in a group administered
TDF during the first 24 weeks in a previous study [3].
Therefore, monitoring of renal function should be pri-
marily conducted during the first 24 weeks after initiat-
ing a TDF-containing cART regimen.
Plasma TFV trough concentrations showed a stronger
correlation with the rate of decrease in eGFR than the other
variables, suggesting that plasma TFV trough concentra-
tions are useful to predict the occurrence of TDF-induced
renal dysfunction. Additionally, the rate of decrease in
eGFR uncorrected for BSA was also significantly correlated
with the plasma TFV trough concentration (Spearman cor-
relation = 0.709, p ≤ 0.025). Furthermore, in the analysis of
the data for the seven patients without concurrent use of a
nephrotoxic drug, the rate of decrease in eGFR was signifi-
cantly correlated with plasma TFV trough concentrations
(Spearman correlation = 0.900, p < 0.011). The significant
correlation between the rate of decrease in eGFR and
plasma TFV trough concentrations supports the findings of
a previous study in which high plasma TFV trough concen-
trations were associated with a decrease in eGFR [5]; the
median decrease in eGFR at 12 months after cART initi-
ation was 8.5 mL/min in the group with high plasma TFV
trough concentrations (>90 ng/mL). In the present study,
three patients had high plasma TFV trough concentrations
(>90 ng/mL), with decreases in eGFR at 48 weeks after
cART initiation of 22.3, 29.4, and 57.2 mL/min. Therefore,
the impact of higher plasma TFV trough concentrations on
eGFR is greater in Japanese patients. In addition, the occur-
rence of TDF-induced renal dysfunction might be predicted
Fig. 1 Correlation analysis between eGFR decrease rate and potential variables associated with renal dysfunction. Patients with renal dysfunction
are indicated by black circles, and patients without renal dysfunction are indicated by white triangles. eGFR, estimated glomerular filtration rate;
BMI, body mass index; TFV, tenofovir
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from higher plasma TFV trough concentrations in Japanese
patients. The rate of decrease in eGFR and body weight or
BMI was also significantly and negatively correlated, sug-
gesting that the development of TDF-induced renal dys-
function is affected by low body weight and BMI. Low body
weight was also associated with TDF-induced renal dys-
function in a previous report [4], and plasma TFV concen-
trations can be affected by low body weight, genetic
polymorphisms of drug transporter genes, and other factors
[11]. Additionally, in a study with women, decreasing BMI
and other factors were associated with elevated TFV expos-
ure [12]. When measurement of plasma TFV trough con-
centrations for individual monitoring purposes in Japanese
patients is not possible, we suggest that low body weight or
low BMI could serve as a reasonable alternative predictor
of TDF-induced renal dysfunction.
Our study has several limitations. First, the main limi-
tation of our study is the small sample size. Future stud-
ies are needed to replicate our results with a larger
sample size. Second, formulations containing TDF are
only available in oral tablets, and powder formulations
for the purposes of dose adjustment do not exist in
Japan. To reduce the single dose amount and extend the
dosing interval (e.g., every 48 h), crushed tablets could
be used to control higher plasma TFV trough concentra-
tions. However, this could cause issues with maintaining
medication adherence. Therefore, reducing the dose of
TDF based on TDM is not currently easy.
Conclusions
In conclusion, this study showed that higher plasma
TFV trough concentrations are associated with a de-
crease in eGFR in Japanese patients, and plasma TFV
trough concentrations might predict the occurrence of
TDF-induced renal dysfunction. In the future, to prevent
TDF-induced renal dysfunction, reduction of the TDF
dose or a switch from TDF to a different ARV could be
considered with high plasma TFV trough concentrations.
Although more studies are needed to identify the factors
related with TDF-induced renal dysfunction, we believe
that the use of plasma TFV trough concentrations could
help prevent this adverse event.
Additional file
Additional file 1 Data regarding the 11 patients. (XLSX 10 kb)
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